The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis
Open accessAbstract
In two murine models of the human inflammatory bowel diseases, treatment with ethyl pyruvate ameliorated multiple features of active colitis, possibly by inhibiting expression and release of the damage-associated molecular pattern molecule HMGB1 from inflamed intestinal mucosa. Signals from stressed cells and the enteric microbiota activate macrophages and dendritic cells and mediate intestinal inflammation. HMGB1 serves as an immunogenic stimuli causing release of inflammatory cytokines by myeloid cells. Ethyl pyruvate inhibits secretion of HMGB1 and improves survival in models of endotoxemia and hemorrhagic shock. We reasoned that ethyl pyruvate may be protective in colitis, which involves similar inflammatory pathways. In IL-10−/− mice with established chronic colitis, ethyl pyruvate administration ameliorated colitis and reduced intestinal cytokine production. IL-10−/− mice demonstrated increased intestinal HMGB1 expression and decreased expression of RAGE compared with wild-type mice. Fecal HMGB1 levels were decreased in ethyl pyruvate-treated mice. Furthermore, ethyl pyruvate induced HO-1 expression in intestinal tissue. In TNBS-induced colitis, intrarectal administration of ethyl pyruvate resulted in amelioration of colitis and reduced intestinal cytokine production. In LPS-activated murine macrophages, ethyl pyruvate decreased expression of IL-12 p40 and NO production but did not affect IL-10 levels. Ethyl pyruvate did not inhibit nuclear translocation of NF-κB family members but attenuated NF-κB DNA binding. Additionally, ethyl pyruvate induced HO-1 mRNA and protein expression and HO-1 promoter activation. Moreover, ethyl pyruvate prevented nuclear-to-cytoplasmic translocation of HMGB1. In conclusion, the HMGB1/RAGE pathway has pathophysiologic and diagnostic significance in experimental colitis. Ethyl pyruvate and other strategies to inhibit HMGB1 release and function represent promising interventions in chronic inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unravelling the pathogenesis of inflammatory bowel disease
Xavier, R. J., & Podolsky, D. K. (2007) · Nature · doi:10.1038/nature06005 · Cited by 4,364
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221 · cited 1×
“HMGB1 is actively secreted by immunostimulated macrophages [4] and enterocytes [5] and is released by necrotic but not apoptotic cells [6].”
BackgroundRole of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase.
Xie, Q. W., Kashiwabara, Y., & Nathan, C. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37600-7 · Cited by 2,212 · cited 1×
“NF-B family members have been implicated as key activators of inflammatory responses [41, 42 ].”
BackgroundHMGB1 SIGNALS THROUGH TOLL-LIKE RECEPTOR (TLR) 4 AND TLR2
Yu, M., Wang, H., Ding, A., Golenbock, D. T., Latz, E., Czura, C. J., Fenton, M. J., Tracey, K. J., & Yang, H. (2006) · Shock · doi:10.1097/01.shk.0000225404.51320.82 · Cited by 832 · cited 3×
“There are several defined receptors for HMGB1 including RAGE [11], TLR2, and TLR4 [12, 13].”
BackgroundInside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox
Rubartelli, A., & Lotze, M. T. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.08.004 · Cited by 614
Self-citation
Cited by
Immunopathogenesis of IBD: current state of the art
de Souza, H. S. P., & Fiocchi, C. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.186 · Cited by 1,551
HMGB1 is a therapeutic target for sterile inflammation and infection
Andersson, U., & Tracey, K. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101323 · Cited by 1,437
“Decreased release due to nuclear retention (52, 53)”
BackgroundDAMPening Inflammation by Modulating TLR Signalling
Piccinini, A. M., & Midwood, K. S. (2010) · Mediators of Inflammation · doi:10.1155/2010/672395 · Cited by 973
Kang, R., Chen, R., Zhang, Q., Hou, W., Wu, S., Cao, L., Huang, J., Yu, Y., Fan, X.-G., Yan, Z., et al. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.05.001 · Cited by 956
Self-citationThe mechanism of HMGB1 secretion and release
Chen, R., Kang, R., & Tang, D. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00736-w · Cited by 849
High-mobility group box 1 and cancer
Tang, D., Kang, R., Zeh III, H. J., & Lotze, M. T. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.11.014 · Cited by 512
Self-citationHigh-Mobility Group Box 1, Oxidative Stress, and Disease
Tang, D., Kang, R., Zeh, H. J., & Lotze, M. T. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3356 · Cited by 468
Self-citationToll-like receptors in inflammatory bowel diseases: A decade later
Cario, E. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21282 · Cited by 336
An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies
Musumeci, D., Roviello, G. N., & Montesarchio, D. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.001 · Cited by 334
Sterile inflammation and pregnancy complications: a review
Nadeau-Vallée, M., Obari, D., Palacios, J., Brien, M.-È., Duval, C., Chemtob, S., & Girard, S. (2016) · Reproduction · doi:10.1530/rep-16-0453 · Cited by 275
High‐mobility group box‐1 in sterile inflammation
Tsung, A., Tohme, S., & Billiar, T. R. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12276 · Cited by 187
HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis
Hernandez, C., Huebener, P., Pradere, J.-P., Antoine, D. J., Friedman, R. A., & Schwabe, R. F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci91786 · Cited by 110
Metadata
- Authors
- Davé, S. H., Tilstra, J. S., Matsuoka, K., Li, F., DeMarco, R. A., Beer-Stolz, D., Sepulveda, A. R., Fink, M. P., Lotze, M. T., & Plevy, S. E.
- Venue
- Journal of Leukocyte Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-05-19
- Volume
- 86
- Issue
- 3
- Pages
- 633-643
- ISSN
- 0741-5400 (ISSN-L)
- 1938-3673
- OpenAlex
- W2139680138
- Cited by
- 170
- References
- 5
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.